23.5 SUMMARY 23 • 21Exhibit 23.11. Targets and Progress Against Target from P9 of Novo Nordisk’s Report-
ing on the Triple Bottom Line, 2001.
Section Target Status
Integrated 2001 Develop a set of key performance indicators for social • • •
responsibility and the other elements of the Triple Bottom Line,
p. 10
Social 2001 Complete the initial review of social responsibility and develop • • •
a strategy for implementation, p. 8
2001 Ensure that there is no significant increase in the frequency of • • •
occupational injuries at work and wherever possible continue to
achieve reductions, p. 30
2001 Collect background information from each production unit and •
country on factors that have relevance to the number of accidents
reported, p. 30
2001–02 Develop business strategies for equal opportunities in the • •
workplace, p. 35
2001–02 Engage in dialogue with selected key suppliers and carry out pilot • • •
projects regarding social considerations in supplier and contractor
evaluation, p. 38
2001–02 Investigate how Novo Nordisk can improve the health of people • •
in the organisation
2001–02 Conclude and communicate the findings of the DAWN (Diabetes • • •
Attitudes, Wishes and Needs) study to uncover behavioural, social
and psychosocial aspects of diabetes, p. 26
2001–02 Initiate the development of a ‘sustainable business model’ for • •
helping people with diabetes in poor countries to gain access to
diabetes care, p. 20
2001–02 Assist in the development and implementation of national diabetes • •
strategies, p. 26
Environmental 2001 Increase the eco-productivity for energy by 4 percentage points, p. 52 • • •
2001 Increase the eco-productivity for water by 5 percentage points, p. 52 •
2001–02 Further involve employees in the implementation of ISO 14001 • •
globally, p. 50
2001–02 Improve methods for reporting transport emissions and use the • •
results to reduce the environmental impact, in co-operation with
our transport suppliers, p. 55
2001 Continue working towards the replacement and/or removal of • • •
antibiotic resistance marker genes in our production strains, p. 49
2001 Establish Novo Nordisk principles for the future use of human • • •
materials in drug discovery and development as part of
implementing the Council of Europe’s Convention on Human Rights
and Biomedicine, p. 44
2001 Remove animal testing for the product control of 29 selected material • •
codes, p. 40
2001–02 Implement improvements in the housing conditions for experimental • •
animals in consideration of the needs of the animals, p. 40
2001 Formalise and further develop an internal ethical review process for • • •
experiments on animals, p. 40
- • • achieved
- • progress made
- not achieved, included in new targets
Following Up Targets
Novo Nordisk is committed to continuous improvement in our environmental, social and economic per-
formance. Setting high objectives and targets and reporting on progress in meeting those goals are core
elements of the Novo Nordisk Way of Management. The table shows how targets were met in 2001. For
details, see the Internet version of this report.